No Data
No Data
AIM Vaccine Insider Ups Holding By 27% During Year
AIM Vaccine Submits Pre-Applications for Clinical Trials for MRNA RSV, Shingles Vaccines
HKEX Announcement Nuggets | CStone Pharmaceuticals - B(02616): Latest data from the first human study of core product CS5001 (ROR1 ADC) will be released at the 2024 ASCO Meeting.
【Important matter】The Amy vaccine (06660) has submitted clinical trial pre-applications for two mRNA vaccines for respiratory syncytial virus (RSV) and herpes zoster, respectively. Stone Pharmaceutical-B (02616): The latest data on the first human study of the core product CS5001 (ROR1 ADC) will be released at the 2024 ASCO conference. Kejia Pharmaceutical-B (02171) updated the results of the CT041 study presented in Nature Medicine and the 2024 ASCO annual meeting. Xingye Holdings (00132) plans to increase capital to Green Gold Leasing by approximately 141 million yuan.
AIM ImmunoTech (06660.HK) has submitted clinical trial pre-applications for two mRNA vaccines for respiratory syncytial virus (RSV) and shingles.
On June 4th, Gelonghui announced that AIMMUNE (06660.HK) actively promotes the development of vaccine pipeline products in accordance with the established company's global strategy, using the advantage of mRNA technology platform and continuously innovating technologies to rapidly advance the research and development of mRNA vaccine series products. In June 2024, AIMMUNE submitted pre-clinical trial applications for respiratory syncytial virus (RSV) mRNA vaccines and herpes zoster mRNA vaccines to the Drug Evaluation Center of the National Medical Products Administration. 1. About the Respiratory Syncytial Virus (RSV) mRNA Vaccine: RSV is a common respiratory infection pathogen with high virulence.
Take Care Before Jumping Onto AIM Vaccine Co., Ltd. (HKG:6660) Even Though It's 26% Cheaper
Hong Kong Stock Concept Tracking | US Confirms Second Case of Human Infection with Avian Influenza Vaccine Sector Receives Attention (with concept stocks)
On May 22, local time, according to reports from local health officials, the US state of Michigan has confirmed the state's second case of human infection with bird flu. The infected person was a farm worker who had mild symptoms and quickly recovered after being infected. According to reports, this is the third case of bird flu reported across the US this year. Last month, a farm worker in the southern US state of Texas developed symptoms such as red eyes after being exposed to sick cows. This is the first case of bird flu in the US this year. The US side confirmed the second case of human infection with bird flu on Wednesday. Affected by this, vaccine concept stocks rose across the board. BioNTech was up 11.1% by the close, CureV
No Data